Cargando…
Early versus later response to treatment in patients with community-acquired pneumonia: analysis of the REACH study
BACKGROUND: Key goals in the treatment of CAP include early response to treatment and achievement of clinical stability. The US FDA recommends early response endpoints (72 hours after initiation of treatment) in clinical trials for the treatment of community-acquired bacterial pneumonia. REACH (REtr...
Autores principales: | Blasi, Francesco, Ostermann, Helmut, Racketa, Jill, Medina, Jesús, McBride, Kyle, Garau, Javier |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3903813/ https://www.ncbi.nlm.nih.gov/pubmed/24450444 http://dx.doi.org/10.1186/1465-9921-15-6 |
Ejemplares similares
-
Resource use by patients hospitalized with community-acquired pneumonia in Europe: analysis of the REACH study
por: Ostermann, Helmut, et al.
Publicado: (2014) -
Current management of patients hospitalized with community-acquired pneumonia across Europe: outcomes from REACH
por: Blasi, Francesco, et al.
Publicado: (2013) -
Early response to antibiotic treatment in European patients hospitalized with complicated skin and soft tissue infections: analysis of the REACH study
por: Garau, Javier, et al.
Publicado: (2015) -
Acute myocardial infarction versus other cardiovascular events in community-acquired pneumonia
por: Aliberti, Stefano, et al.
Publicado: (2015) -
Identify Drug-Resistant Pathogens in Patients with Community-Acquired Pneumonia
por: Amati, Francesco, et al.
Publicado: (2023)